Tag:

Novartis

Latest Headlines

Latest Headlines

What price MS therapy? Thanks to price hikes, $50K-plus, even for decades-old meds

The cost of multiple sclerosis drugs has skyrocketed over the past 20 years, and it's not just new drugs driving that increase. Not one MS drug has a list price of less than $50,000 per year in the U.S., and some treatments cost 7 times more now than they did in 1995, a new study found.

Lilly's Elanco to unload former Novartis vax plant

It has been a rough ride for the former Novartis, former Chiron vaccine plant in Vacaville, CA. Eli Lilly picked it up last year as part of its deal to buy Novartis' animal health assets but has decided it does not need the biologics API facility and so is putting it up for sale.

Lilly, Novartis and Pfizer give trial-patient matching tech to TrialReach

Eli Lilly, Novartis and Pfizer have found a new home for the tech they created to improve ClinicalTrials.gov. The group is giving what it has achieved to date to TrialReach, a tech company developing a patient-focused clinical trial discovery platform.

With GSK swap behind it, Novartis scouts for $2B-$5B buyouts

A little more than a month after completing its big asset swap with GlaxoSmithKline, Novartis CEO Joe Jimenez says he's going back to the bargaining table to look for some bolt-on buyouts in the $2 billion to $5 billion range.

Novartis unleashes M&A scouts as GSK deal starts to deliver on margins

Novartis beat profit estimates for the first quarter, partly because of the big deal closing with GlaxoSmithKline March 2. Now, CEO Joe Jimenez says the Swiss drugmaker is back on the dealmaking trail.

Novartis' 'megablockbuster' heart drug LCZ696 wins another rave preview

Readying itself for what looks like a blockbuster victory lap in the cardiovascular field, Novartis has notched boasting rights for its heart drug LCZ696, gaining recognition in the U.K. as a "promising innovative medicine" that could be made available to patients ahead of formal marketing approval.

CSL CFO to lead flu vaccine business after 2016 launch

Australia's CSL will launch its new global flu vaccine business in early 2016, after it completes its $275 million acquisition of Novartis' flu vaccine unit.

Gunning for a spot in the next-gen autoimmune market, Lilly med hits goals in latest trial

Eli Lilly's closely watched autoimmune treatment ixekizumab met its main goals in a Phase III psoriatic arthritis trial, rolling toward an FDA application and a shot at competing in a fast-crowding space.

Novartis' new CAR-T hopeful looks safe in an early solid tumor study

A novel immuno-oncology treatment from Novartis and the University of Pennsylvania came through in an early safety study on patients with solid tumors, encouraging investigators and burnishing its potential.

Alcon intraocular lens gets FDA's stringent PMA approval

Novartis' Alcon received FDA approval for its implantable AcrySof IQ ReSTOR +2.5 Diopter intraocular lens, enabling vision correction at all distances in eye care patients with or without presbyopia who undergo cataract surgery.